BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

232 related articles for article (PubMed ID: 21931799)

  • 1. Gene expression signature analysis identifies vorinostat as a candidate therapy for gastric cancer.
    Claerhout S; Lim JY; Choi W; Park YY; Kim K; Kim SB; Lee JS; Mills GB; Cho JY
    PLoS One; 2011; 6(9):e24662. PubMed ID: 21931799
    [TBL] [Abstract][Full Text] [Related]  

  • 2. DNA microarray profiling of genes differentially regulated by the histone deacetylase inhibitors vorinostat and LBH589 in colon cancer cell lines.
    LaBonte MJ; Wilson PM; Fazzone W; Groshen S; Lenz HJ; Ladner RD
    BMC Med Genomics; 2009 Nov; 2():67. PubMed ID: 19948057
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Genistein cooperates with the histone deacetylase inhibitor vorinostat to induce cell death in prostate cancer cells.
    Phillip CJ; Giardina CK; Bilir B; Cutler DJ; Lai YH; Kucuk O; Moreno CS
    BMC Cancer; 2012 Apr; 12():145. PubMed ID: 22494660
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hypoxia-independent gene expression signature associated with radiosensitisation of prostate cancer cell lines by histone deacetylase inhibition.
    Jonsson M; Ragnum HB; Julin CH; Yeramian A; Clancy T; Frikstad KM; Seierstad T; Stokke T; Matias-Guiu X; Ree AH; Flatmark K; Lyng H
    Br J Cancer; 2016 Oct; 115(8):929-939. PubMed ID: 27599042
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tissue transglutaminase (TG2) is involved in the resistance of cancer cells to the histone deacetylase (HDAC) inhibitor vorinostat.
    Carbone C; Di Gennaro E; Piro G; Milone MR; Pucci B; Caraglia M; Budillon A
    Amino Acids; 2017 Mar; 49(3):517-528. PubMed ID: 27761756
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Changes in histone deacetylase (HDAC) expression patterns and activity of HDAC inhibitors in urothelial cancers.
    Niegisch G; Knievel J; Koch A; Hader C; Fischer U; Albers P; Schulz WA
    Urol Oncol; 2013 Nov; 31(8):1770-9. PubMed ID: 22944197
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The mechanism of action of the histone deacetylase inhibitor vorinostat involves interaction with the insulin-like growth factor signaling pathway.
    Sarfstein R; Bruchim I; Fishman A; Werner H
    PLoS One; 2011; 6(9):e24468. PubMed ID: 21931726
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Genome-wide functional genomic and transcriptomic analyses for genes regulating sensitivity to vorinostat.
    Falkenberg KJ; Gould CM; Johnstone RW; Simpson KJ
    Sci Data; 2014; 1():140017. PubMed ID: 25977774
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Vorinostat modulates cell cycle regulatory proteins in glioma cells and human glioma slice cultures.
    Xu J; Sampath D; Lang FF; Prabhu S; Rao G; Fuller GN; Liu Y; Puduvalli VK
    J Neurooncol; 2011 Nov; 105(2):241-51. PubMed ID: 21598070
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Weighted gene co-expression network analysis and connectivity map identifies lovastatin as a treatment option of gastric cancer by inhibiting HDAC2.
    Zhang L; Kang W; Lu X; Ma S; Dong L; Zou B
    Gene; 2019 Jan; 681():15-25. PubMed ID: 30266498
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Histone deacetylase 3 inhibits expression of PUMA in gastric cancer cells.
    Feng L; Pan M; Sun J; Lu H; Shen Q; Zhang S; Jiang T; Liu L; Jin W; Chen Y; Wang X; Jin H
    J Mol Med (Berl); 2013 Jan; 91(1):49-58. PubMed ID: 22763818
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Drug library screening identifies histone deacetylase inhibition as a novel therapeutic strategy for choriocarcinoma.
    Watanabe E; Yokoi A; Yoshida K; Sugiyama M; Kitagawa M; Nishino K; Yamamoto E; Niimi K; Yamamoto Y; Kajiyama H
    Cancer Med; 2023 Feb; 12(4):4543-4556. PubMed ID: 36106577
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacological Analysis of Vorinostat Analogues as Potential Anti-tumor Agents Targeting Human Histone Deacetylases: an Epigenetic Treatment Stratagem for Cancers.
    Praseetha S; Bandaru S; Nayarisseri A; Sureshkumar S
    Asian Pac J Cancer Prev; 2016; 17(3):1571-6. PubMed ID: 27039807
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Analysis of the genomic response of human prostate cancer cells to histone deacetylase inhibitors.
    Kortenhorst MS; Wissing MD; Rodríguez R; Kachhap SK; Jans JJ; Van der Groep P; Verheul HM; Gupta A; Aiyetan PO; van der Wall E; Carducci MA; Van Diest PJ; Marchionni L
    Epigenetics; 2013 Sep; 8(9):907-20. PubMed ID: 23880963
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Contribution of reactivated RUNX3 to inhibition of gastric cancer cell growth following suberoylanilide hydroxamic acid (vorinostat) treatment.
    Huang C; Ida H; Ito K; Zhang H; Ito Y
    Biochem Pharmacol; 2007 Apr; 73(7):990-1000. PubMed ID: 17276407
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combining histone deacetylase inhibitor vorinostat with aurora kinase inhibitors enhances lymphoma cell killing with repression of c-Myc, hTERT, and microRNA levels.
    Kretzner L; Scuto A; Dino PM; Kowolik CM; Wu J; Ventura P; Jove R; Forman SJ; Yen Y; Kirschbaum MH
    Cancer Res; 2011 Jun; 71(11):3912-20. PubMed ID: 21502403
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Synthesis and anticancer activity of novel histone deacetylase inhibitors that inhibit autophagy and induce apoptosis.
    Mo H; Zhang R; Chen Y; Li S; Wang Y; Zou W; Lin Q; Zhao DG; Du Y; Zhang K; Ma YY
    Eur J Med Chem; 2022 Dec; 243():114705. PubMed ID: 36215854
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Vorinostat enhances the cisplatin-mediated anticancer effects in small cell lung cancer cells.
    Pan CH; Chang YF; Lee MS; Wen BC; Ko JC; Liang SK; Liang MC
    BMC Cancer; 2016 Nov; 16(1):857. PubMed ID: 27821078
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Vorinostat, a histone deacetylase (HDAC) inhibitor, promotes cell cycle arrest and re-sensitizes rituximab- and chemo-resistant lymphoma cells to chemotherapy agents.
    Xue K; Gu JJ; Zhang Q; Mavis C; Hernandez-Ilizaliturri FJ; Czuczman MS; Guo Y
    J Cancer Res Clin Oncol; 2016 Feb; 142(2):379-87. PubMed ID: 26314218
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Histone deacetylase inhibitors potentiate vesicular stomatitis virus oncolysis in prostate cancer cells by modulating NF-κB-dependent autophagy.
    Shulak L; Beljanski V; Chiang C; Dutta SM; Van Grevenynghe J; Belgnaoui SM; Nguyên TL; Di Lenardo T; Semmes OJ; Lin R; Hiscott J
    J Virol; 2014 Mar; 88(5):2927-40. PubMed ID: 24371063
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.